ArticleOrphanet journal of rare diseases2025
Clinicopathological features, treatment outcomes, and prognostic factors of angiosarcoma: a 21-year experience at one center.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Angiosarcoma Presenting as a Chronic Non-Healing Lower Extremity Ulcer in Lymphoedema: A Challenge.International wound journal · 2026Article
- Article
- Article
- Incidence and Survival of Thoracic Angiosarcoma: Epidemiologic Evidence from a Population-Based Cancer Registry.Cancers · 2026Article
- Angiosarcoma in a soft tissue sarcoma cohort: real-world patterns and outcomes.Frontiers in oncology · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAngiosarcoma is a rare, aggressive soft tissue sarcoma characterized by poor prognosis and limited treatment consensus. Our aim was to clarify the clinicopathological features, treatment outcomes, and prognostic factors of these patients to inform improved management and follow-up strategies.
methodsWe retrospectively analyzed the clinical, pathological, treatment, and survival data of patients with angiosarcoma treated from 2003 to 2024 at Zhejiang Cancer Hospital.
resultsA total of 128 angiosarcoma patients were included, categorized as cutaneous (n = 49), visceral (n = 35), deep soft tissue (n = 31), breast (n = 10), and bone (n = 3). The median progression-free survival (PFS) and overall survival (OS) were 7 and 20 months, respectively, with 2-year PFS of 21.4% and 5-year OS of 29.6%. Superficial cases had better outcomes compared to deep-seated cases, larger tumors (> 5 cm) and distant metastases predicted worse prognosis. Primary surgery improved survival in localized disease, with adjuvant radiotherapy enhancing local control but not OS. In metastatic cases, first-line systemic therapies showed that paclitaxel-based regimens were less effective than doxorubicin-based chemotherapy, and the addition of anti-angiogenic therapy did not improve outcomes.
conclusionThis study underscores the heterogeneity of angiosarcoma across different sites, emphasizing the role of surgery for localized AS, and chemotherapy remains the mainstay for advanced cases. Targeted therapies and immunotherapies offer novel promise, especially the combination strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.